Autopsy report · NCT04007367

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

“Internal company decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 5 months before it stopped.
• 53 participants enrolled.
• Results were posted on the registry 2 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Biogen

Sponsor type

Industry

Conditions

Major Depressive Disorder

Interventions

SAGE-217; Placebo

Participants

53

Sites

46

Countries

United States

Trials that died the same way

• Clinical Performance Evaluation of the Hativ P30
  “Company's internal decision.” (92% match in meaning)
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (82% match in meaning)
• Core Warming of COVID-19 Patients
  “Internal decision” (81% match in meaning)
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
  “internal company decision; not safety related” (79% match in meaning)
• Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
  “Company decision” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.